Truist Financial Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price target cut by analysts at Truist Financial from $21.00 to $18.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price objective suggests a potential upside of 242.86% from the company’s previous close.

Other equities analysts also recently issued research reports about the company. Bank of America dropped their price target on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Wednesday. Morgan Stanley dropped their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday. Oppenheimer began coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price target for the company. Brookline Capital Management assumed coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $19.30.

Y-mAbs Therapeutics Price Performance

Shares of YMAB opened at $5.25 on Wednesday. The firm has a market capitalization of $235.14 million, a price-to-earnings ratio of -9.72 and a beta of 0.65. Y-mAbs Therapeutics has a 1-year low of $4.25 and a 1-year high of $18.17. The company has a 50-day moving average of $6.39 and a 200 day moving average of $10.58.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same period in the prior year, the firm posted ($0.02) EPS. On average, equities analysts anticipate that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several institutional investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at $44,000. KLP Kapitalforvaltning AS acquired a new position in Y-mAbs Therapeutics during the 4th quarter valued at about $46,000. Intech Investment Management LLC purchased a new stake in Y-mAbs Therapeutics in the third quarter valued at about $133,000. ProShare Advisors LLC acquired a new stake in Y-mAbs Therapeutics in the fourth quarter worth about $99,000. Finally, Empire Financial Management Company LLC purchased a new stake in shares of Y-mAbs Therapeutics during the third quarter worth about $210,000. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.